Showing 1181-1190 of 21420 results for "".
- Kidney Protection Strategy Adherence in Critically Ill Adults with AKIhttps://reachmd.com/news/kidney-protection-strategy-adherence-critical-aki/2487549/Key Takeaways Complete bundle adherence was reported in 31% of patients. Sustained MAP optimization had the lowest component-level implementation rate at 33%. Adherence was associated with a lower incidence of AKD beyond day 7, a higher incide
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://reachmd.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- Global Integral Beauty Conference Marks Fifth Anniversary With Expanded International Programhttps://reachmd.com/news/global-integral-beauty-conference-marks-fifth-anniversary-with-expanded-international-program/2487545/Global Integral Beauty (GIB) has announced that its 5th Global Integral Beauty Conference will be held on October 17, 2026, at the New York Marriott Marquis in New York, New York. Now entering its fifth year, the conference s
- Hugel Highlights Global Expansion and K-Aesthetics Leadership at Inaugural AMWC KOREAhttps://reachmd.com/news/hugel-highlights-global-expansion-and-k-aesthetics-leadership-at-inaugural-amwc-korea/2487542/Hugel, Inc. showcased its expanding global presence in medical aesthetics at the inaugural Aesthetic & Anti-aging Medicine World Congress Korea (AMWC KOREA), held June 19-20 in Seoul, South Korea. The meeting brought together approximately 2,000 healthcare professionals and industry leaders f
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://reachmd.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://reachmd.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23
- Paroxetine Linked to Neurovascular and Immune Proteomic Changes in Refractory Rosacea: Analysishttps://reachmd.com/news/paroxetine-linked-to-neurovascular-and-immune-proteomic-changes-in-refractory-rosacea/2487517/A secondary analysis of a randomized clinical trial in JAMA Dermatology identified systemic proteomic changes associated with paroxetine treatment in patients with refractory erythematous rosacea, offering new insight into
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://reachmd.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese
- FAST III: Angiography-Based Physiology vs Pressure-Wire Guidancehttps://reachmd.com/news/fast-iii-angiography-physiology-pressure-wire/2487510/Key Takeaways vFFR-guided and FFR-guided strategies had the same reported 1-year primary-endpoint rate, and the authors concluded noninferiority. FAST III was an international, open-label, randomized noninferiority trial at 37 European sites in patient
- Olaparib Plus Radium-223 Improves rPFS in COMRADEhttps://reachmd.com/news/olaparib-radium-223-rpfs-comrade/2487511/Key Takeaways Olaparib plus radium-223 was associated with longer investigator-assessed radiographic progression-free survival than radium-223 alone. Longer radiographic progression-free survival was most pronounced without prior docetaxel and with 20